Your browser doesn't support javascript.
loading
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca, Paula; Foy, Victoria; Raby, Sophie; Carmona-Bayonas, Alberto; Macía-Rivas, Lola; Arrazubi, Virginia; Cacho Lavin, Diego; Hernandez San Gil, Raquel; Custodio, Ana; Cano, Juana María; Fernández Montes, Ana; Mirallas, Oriol; Macias Declara, Ismael; Vidal Tocino, Rosario; Visa, Laura; Limón, María Luisa; Pimentel, Paola; Martínez Lago, Nieves; Sauri, Tamara; Martín Richard, Marta; Mangas, Monserrat; Gil Raga, Mireia; Calvo, Aitana; Reguera, Pablo; Granja, Mónica; Martín Carnicero, Alfonso; Hernández Pérez, Carolina; Cerdá, Paula; Gomez Gonzalez, Lucía; Garcia Navalon, Francisco; Pacheco Barcia, Vilma; Gutierrez Abad, David; Ruiz Martín, Maribel; Weaver, Jamie; Mansoor, Wasat; Gallego, Javier.
Afiliación
  • Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain.
  • Foy V; Department of Medical Oncology, Christie Hospital, Manchester, UK.
  • Raby S; Department of Medical Oncology, Christie Hospital, Manchester, UK.
  • Carmona-Bayonas A; Medical Oncology Department, Hospital Universitario Morales Meseguer, Calle Marqués de los Vélez, s/n, Murcia 30007, Spain.
  • Macía-Rivas L; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Arrazubi V; Medical Oncology Department, Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.
  • Cacho Lavin D; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Hernandez San Gil R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain.
  • Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain.
  • Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
  • Fernández Montes A; Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain.
  • Mirallas O; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Macias Declara I; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain.
  • Vidal Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain.
  • Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain.
  • Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Pimentel P; Medical Oncology Department, Hospital General Universitario Santa Lucía, Cartagena, Spain.
  • Martínez Lago N; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Sauri T; Medical Oncology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Martín Richard M; Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain.
  • Mangas M; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain.
  • Gil Raga M; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
  • Calvo A; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Reguera P; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Granja M; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Martín Carnicero A; Medical Oncology Department, Hospital San Pedro, Logroño, Spain.
  • Hernández Pérez C; Medical Oncology Department, Hospital Universitario Nuestra Señora de the Candelaria, Santa Cruz de Tenerife, Spain.
  • Cerdá P; Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain.
  • Gomez Gonzalez L; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain.
  • Garcia Navalon F; Medical Oncology Department, Hospital Universitario Son Llatzer, Mallorca, Spain.
  • Pacheco Barcia V; Medical Oncology Department, Hospital Universitario de Torrejón, Madrid, Spain.
  • Gutierrez Abad D; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Ruiz Martín M; Medical Oncology Department, Hospital Universitario Rio Carrión de Zamora, Zamora, Spain.
  • Weaver J; Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, UK.
  • Mansoor W; Department of Medical Oncology, Christie Hospital/University of Manchester, Manchester, UK.
  • Gallego J; Medical Oncology Department, Hospital General Universitario of Elche, Elche, Spain.
Ther Adv Med Oncol ; 15: 17588359231157641, 2023.
Article en En | MEDLINE | ID: mdl-36895850
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2023 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2023 Tipo del documento: Article País de afiliación: España